Quantcast

Latest Caphosol Stories

2010-06-24 07:30:00

DALLAS and NEW YORK, June 24 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical...

2010-06-15 07:30:00

DALLAS and NEW YORK, June 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has initiated a broad-scale MuGard Centers-of-Excellence Sampling Program with leading oncology networks for its lead product, MuGard, a FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments. (Photo:...

2010-04-15 07:30:00

DALLAS and NEW YORK, April 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it is collaborating with leading expert in oral mucositis ("OM"), Stephen T. Sonis, DMD, DMSc, Chief of the Division of Oral Medicine at the Dana Farber Cancer Institute and Program Director for Supportive Cancer Care at Clinical Assistance Programs, LLC ("CAP"), to further...

2010-04-13 07:30:00

DALLAS and NEW YORK, April 13 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that it has completed its first commercial scale production run of MuGard in North America at Accupac, Inc. manufacturing facilities outside Philadelphia. Access intends to use the initial batches of MuGard for pre-launch key institution evaluations, preliminary stock for select wholesalers and specialty distributors, and additional post-approval studies to be conducted...

2010-03-25 07:30:00

DALLAS, March 25 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that JCOM Co., Ltd., its Korean licensee for both MuGard(TM) and ProLindac(TM), has received approval from the Korean Food and Drug Administration (KFDA) of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis. Under the agreement, JCOM is responsible for obtaining the necessary regulatory approvals for MuGard in Korea....

2010-01-21 12:02:00

Growing Use of Oral Chemotherapeutics Brings Clinical Benefits, Raises Questions in Prescribing, Adherence, Accessibility and Long Term Follow-Up Care According to Panel WASHINGTON, Jan. 21 /PRNewswire-USNewswire/ -- US Oncology, Inc. partnered with the Association of Community Cancer Centers, Association of Oncology Social Work, American Society for Clinical Oncology, Community Oncology Alliance, Oncology Nursing Society and the National Patient Advocate Foundation in hosting a panel...

2009-12-15 08:00:00

DALLAS, Dec. 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today announced the appointment of Frank Jacobucci to the position of Vice President, Sales and Marketing. Mr. Jacobucci will be primarily responsible for the Company's marketing launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy. Mr. Jacobucci has over 20 years experience in sales management, including...

2009-11-12 15:30:00

MINNEAPOLIS/ST. PAUL, Nov. 12 /PRNewswire/ -- New research findings presented today at the Society for Integrative Oncology's (SIO) Sixth International Conference in New York show promise in assessing the efficacy and safety of complementary and alternative medicine (CAM) using traditional research methods. Susan Sencer, MD, Medical Director, Hematology/Oncology at Children's Hospitals and Clinics of Minnesota (Children's), presented findings on the use of the homeopathic agent Traumeel...

2009-09-01 08:00:00

DALLAS, Sept. 1 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board : ACCP) announced today that Access will present at the Rodman & Renshaw 11th Annual Healthcare Conference to be held September 9-11, 2009 at the New York Palace Hotel in New York City. Jeffrey B. Davis, President and CEO of Access is scheduled to speak on Friday, September 11, 2009 at 10:50 am EDT in the Fahnestock Salon (5th Floor) and will give a corporate overview and discuss the Company's...

2009-07-29 08:00:00

DALLAS, July 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced today that it is evaluating strategic options for the commercialization of MuGard in North America. MuGard is an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy, and previously announced data suggest that the market for MuGard is significantly greater than previously expected. Frank Jacobucci, formerly President &...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related